Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

This first-in-class ASO replicates the protective effects of naturally occurring CD33 loss-of-function variants, which are associated with increased resilience to neurodegenerative disease, reduced ...

The small interfering RNA (siRNA) therapy, designed to reduce triglyceride levels by suppressing production of apolipoprotein ...

As the biopharma world predominantly zeroes in on late-stage assets, Eli Lilly is prioritizing early science with the opening ...

ST GenBio achieved triple-digit growth in operating profit in the third quarter of this year, driven by strong performance in its oligonucleotide new ...

Patients with severe hypertriglyceridemia have an increased risk of acute pancreatitis. The efficacy and safety of olezarsen, ...

Korro Bio saw its stock reach all-time lows on disappointing data for its lead pipeline candidate, while Intellia Therapeutics saw analyst downgrades on safety concerns despite releasing positive data ...

Ionis is planning a supplemental submission by the end of the year to expand Tryngolza into severe hypertriglyceridemia. If ...

Arrowhead Pharmaceuticals faces key FDA decisions, legal challenges, and trial results. Read the latest analysis on the stock ...

Korro Bio delivered a double whammy of bad news, reporting lackluster data on its lead candidate and a pause to its partnership with Novo Nordisk. The biotech, which suffered a 79% stock drop in the ...

The regulator backed the medicine after phase 3 data showed dramatic reductions in HAE attacks and sustained disease control ...

Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase ...